Michael Dilling, Ph.D.
Executive Director, Commercialization, Technology Management, Baylor College of Medicine
The Director of the Baylor Licensing Group (BLG), the technology licensing team at Baylor College of Medicine, a leading biomedical research institution and the only private medical school in the Southwestern United States. Responsible for managing the activities of five licensing professionals, an industry agreements professional, and two administrators. Currently leading efforts at BCM to restructure technology commercialization efforts to increase effectiveness and improve outcomes. Guided the development and launch of an online disclosure application to simply faculty interaction with BLG. Responsible for spearheading collaborative efforts with BCM Technologies (BCMT), BCM's wholly-owned venture development subsidiary, to identify and catalyze the formation of new start-up companies. Serves on the Board of Directors for mAbVista, Inc., a new BCM start-up company dedicated to the production of monoclonal antibodies.
Fifteen years technology transfer experience managing a diverse portfolio of biomedical technologies in a leading university technology transfer program with a focus on producing licensing outcomes. Strong pragmatic, principled focus on finding common ground to get deals closed and executed so that important innovations can get to the market and be developed into new products.
Negotiated and closed over 80 license/option agreements, including exclusive licenses for therapeutics, vaccine technologies, gene therapy and immunotherapy technologies, and medical devices. A number of the exclusive licenses were transactions involving equity as part of the license consideration. I have also negotiated and closed many non-exclusive licenses for research tool technologies - knockout mice/cell lines/DNA constructs, etc. I have also licensed software. A number of technologies that I have licensed are now in clinical development, including a T-cell-based vaccine against multiple sclerosis, a vaccine against Norwalk and associated noroviruses, and an immunotherapeutic cancer vaccine.
Negotiation of exclusive and non-exclusive license agreements for biomedical technologies.
Negotiation of other university/industry agreements including sponsored research agreements, confidential disclosure agreements, research collaboration/partnership agreements, clinical trial agreements, testing agreements.
Coordination of patent prosecution strategy with outside legal counsel.
Marketing of technologies to potential industry partners.